|

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

RECRUITINGSponsored by University of Colorado, Denver
Actively Recruiting
SponsorUniversity of Colorado, Denver
Started2024-01-22
Est. completion2029-01
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
Locations4 sites
View on ClinicalTrials.gov →

NCT06397677

Summary

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria
* 18 years of age or older

Exclusion Criteria:

* Prior medication treatment specifically for RA-ILD
* Inability to give informed consent
* Pregnant women

Conditions3

ArthritisInterstitial Lung DiseaseRheumatoid Arthritis

Locations4 sites

California

1 site
University of California San Francisco
San Francisco, California, 94143
Paul Wolters, MD

Colorado

1 site
University of Colorado Denver
Aurora, Colorado, 80045
Haylie A Lengel970-376-8303haylie.lengel@cuanschutz.edu

Kansas

1 site
University of Kansas
Kansas City, Kansas, 66103
Scott Matson, MD

Michigan

1 site
University of Michigan
Ann Arbor, Michigan, 48109
Justin Oldham, MD

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.